Company Filing History:
Years Active: 2006
Title: A Spotlight on Inventor David J. Hermann
Introduction: David J. Hermann, based in Chelsea, Michigan, is a notable inventor in the field of pharmacological modeling. With a focus on enhancing the way drug models are developed, Hermann's innovations aim to streamline one of the most complex processes in pharmaceutical research. His dedication to advancing technology in drug modeling has resulted in significant contributions to the industry.
Latest Patents: Hermann holds a patent for an "Interactive Graphical Environment for Drug Model Generation." This patent presents a method for interactively constructing pharmacological computational models using a graphical user interface. Users can place and connect objects that represent various pharmacokinetic and pharmacodynamic elements. As they do so, these objects are converted into an internal format that effectively represents the statements of the corresponding computational model. Notably, this system allows for the immediate verification of the model through a summarized form, which can include surface syntax for key equations or graphical representations of selected variables' behaviors.
Career Highlights: David J. Hermann is currently employed at Pharsight Corporation, a company renowned for its contributions to drug development and related software solutions. His work focuses on creating user-friendly interfaces that help researchers efficiently visualize and verify complex pharmacological models.
Collaborations: Throughout his career, Hermann has collaborated with distinguished professionals, including Michael Robert Dunlavey and Jeffrey Alan Wald. These partnerships enhance the innovative potential behind his projects, allowing for a more robust approach to drug modeling and research.
Conclusion: David J. Hermann exemplifies the spirit of innovation in the pharmaceutical field. His patent for an interactive graphical environment demonstrates a significant leap in how drug models are constructed and validated. As he continues to work with fellow experts at Pharsight Corporation, his contributions are likely to propel advancements in drug modeling technology, ultimately benefiting the pharmaceutical industry and improving patient outcomes.